By disrupting the interaction between glucokinase and its regulatory protein, scientists at Amgen Inc. have managed to specifically affect high blood sugar levels in mouse models of diabetes, while having no effect on animals with normal blood sugar.
An antibiotic that was once dropped from clinical development because bacteria quite easily develop genetic resistance to it may get a second lease on life – because as part of a combination therapy, it can kill so-called bacterial persisters in biofilms.
To be of any use at all, scientific experiments need to be reproducible. And it has become increasingly clear over the past few years that far too many of them aren’t.
By reactivating a gene that is normally active in embryonic and fetal tissues, but largely silent after birth, researchers have managed to improve the abilities of some adult tissues to grow and repair themselves after injury.
When the abstracts for the upcoming annual meeting of the American Society for Hematology were released last week, results of Geron Corp.’s Imetelstat were the biggest attention-grabber as far as the market was concerned. (See BioWorld Today, Nov. 8, 2013.)
Abstracts of the data that are to be presented at the American Society of Hematology’s annual meeting next month were released Thursday. And the biggest market response to trial data involved Geron Corp’s myelofibrosis drug Imetelstat.
Scientists have identified an enzyme whose function is important for the survival of tuberculosis bacteria regardless of whether they are currently dividing or not.
Scientists have picked apart the role of scarring after spinal cord injury and found that there is at least one component of the glial scar that is helpful for tissue regeneration.
Scientists have developed a method to shield transplanted cells from the transplant recipient’s immune system, enabling them to transplant a diabetic patient with insulin-producing islet cells that remained invisible to his immune system.
Researchers have developed a nanoparticle, made up of siRNAs around a gold core, that could cross the blood-brain barrier and, in animals, silence a gene that is overexpressed most cases of glioblastoma multiforme.
